LIFE SCIENCES, PHARMACEUTICALS & MEDICAL DEVICES
is focused on a new proprietary class of molecules known as Recombinant
T cell receptor Ligands (RTLs) that can be tailored to treat multiple
autoimmune diseases. Artielle has developed a lead compound for
multiple sclerosis called RTL1000, which has received Orphan Drug
status from the U.S. Food and Drug Administration
(nasdaq: AVII) is a pioneer in developing antisense pharmaceuticals to
treat debilitating diseases. Cascadia invested in AVI in 1987 and
worked closely with the Company up to and beyond its 1995 IPO.
Blacktoe Medical designs, develops, and manufactures high-performance, miniaturized
ultrasound probe solutions which combine ultrasound technology with an
innovative physical probe design. The Blacktoe ultrasound probe
combines imaging and touch technology together into a single package to
improve diagnostic effectiveness, increase patient satisfaction, and
has the potential to revolutionize the ultrasound imaging industry
streamlines healthcare communications among patients, providers,
pharmacies and health plans with secure messaging, electronic
prescribing, disease management and contract management technologies.
Lemnagene, acquired by Biolex, 2004, is a biomanufacturing company
using the aquatic plants as a production platform for a full range of
biomanufacturing services to the Pharmaceutical, Vaccine, Veterinarian,
Diagnostic, Nutraceutical and Industrial Protein markets.
acquired Northwest NeuroLogic for its discovery and development of
novel therapeutics for neuropsychiatric, neuroinflammatory and
neurodegenerative diseases and disorders.
is a leader in the emerging field of Leucocyte Population Modulation
therapy. The Company's proprietary family of compounds has potential
therapeutic benefit in autoimmune disease, inflammatory disease,
respiratory conditions and traumatic brain injury.
(nasdaq: OXIS) focuses on developing technologies and products to
diagnose, treat and prevent diseases associated with damage from free
radicals and reactive oxygen species - diseases of oxidative stress.
The Company was acquired in 2006.
(nasdaq: SLXP) develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases.
specializes in developing recombinant therapeutics in a family of
prodrugs that are activated by disease-associated proteases.
Twinstrand's molecules have numerous potential applications against
diseases such as cancer, HIV/AIDS, hepatitis A and C, cytomegalovirus
and herpes.
is a privately held biotechnology company identifying and obtaining
outstanding early-stage technologies. The Company manages and develops
these technologies to a critical phase then spins off the developed
technologies into new start-up companies.
acquired by GE Healthcare, brings the Internet to the point of care
with eHealthcare products and services for physicians and their
patients. The company offers the leading online medical record software
for integrated delivery networks nationwide.
